Wednesday, June 10, 2026

pharma Β· Cystic Fibrosis Β· Hepatitis C

Vertex Pharmaceuticals (Australia)

Vertex Pharmaceuticals (Australia) clinical programs β€” 61 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
Status
Public
HQ
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
Founded
1989
Employees
6,304
Programs
159
Drugs
64
Patents
991
Intelligence Β· Clinical Programs

Vertex Pharmaceuticals (Australia) projects

61 ClinicalTrials.gov programs sponsored by Vertex Pharmaceuticals (Australia).

Vertex Pharmaceuticals (Australia) has 61 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    3 trials
  2. VX-787

    Vertex Pharmaceuticals (Australia) Pty.

    Influenza Virus

    phase 2 small molecule completed

    1 trial
  3. VX-814

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  4. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  5. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial
  6. VX-950

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    2 trials
  7. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial
  8. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    1 trial
  9. VX23-670-001

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial
  10. VX24-993-103

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial
  11. biricodar dicitrate

    Vertex Pharmaceuticals (Australia) Pty.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial
  12. telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule terminated

    1 trial
  13. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vertex Pharmaceuticals (Australia) have?

61 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.